Standout Papers

Metabolic Syndrome With and Without C-Reactive Protein as a Predictor of Coronary Heart Disease... 2003 2026 2010 2018 1.2k
  1. Metabolic Syndrome With and Without C-Reactive Protein as a Predictor of Coronary Heart Disease and Diabetes in the West of Scotland Coronary Prevention Study (2003)
    Naveed Sattar, Allan Gaw et al. Circulation
  2. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials (2019)
    Søren Lund Kristensen, Rasmus Rørth et al. The Lancet Diabetes & Endocrinology
  3. EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis (2009)
    M.J. Peters, Deborah Symmons et al. Annals of the Rheumatic Diseases
  4. Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials (2009)
    Kausik K. Ray, Sreenivasa Rao Kondapally Seshasai et al. The Lancet
  5. Mortality and Cardiovascular Disease in Type 1 and Type 2 Diabetes (2017)
    Aidin Rawshani, Araz Rawshani et al. New England Journal of Medicine
  6. Risk Factors, Mortality, and Cardiovascular Outcomes in Patients with Type 2 Diabetes (2018)
    Aidin Rawshani, Araz Rawshani et al. New England Journal of Medicine
  7. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials (2021)
    Naveed Sattar, Matthew M.Y. Lee et al. The Lancet Diabetes & Endocrinology
  8. Separate and combined associations of body-mass index and abdominal adiposity with cardiovascular disease: collaborative analysis of 58 prospective studies (2011)
    David Wormser, Stephen Kaptoge et al. The Lancet
  9. Explaining How “High-Grade” Systemic Inflammation Accelerates Vascular Risk in Rheumatoid Arthritis (2003)
    Naveed Sattar, David McCarey et al. Circulation
  10. Plasma Leptin and the Risk of Cardiovascular Disease in the West of Scotland Coronary Prevention Study (WOSCOPS) (2001)
    A. Michael Wallace, Alex D. McMahon et al. Circulation
  11. Pravastatin and the Development of Diabetes Mellitus (2001)
    Dilys J. Freeman, John Norrie et al. Circulation
  12. Associations of type 1 and type 2 diabetes with COVID-19-related mortality in England: a whole-population study (2020)
    Emma Barron, Chirag Bakhai et al. The Lancet Diabetes & Endocrinology
  13. Trial of Atorvastatin in Rheumatoid Arthritis (TARA): double-blind, randomised placebo-controlled trial (2004)
    David McCarey, Iain B. McInnes et al. The Lancet
  14. Pregnancy complications and maternal cardiovascular risk: opportunities for intervention and screening? (2002)
    Naveed Sattar et al. BMJ
  15. C-Reactive Protein Is an Independent Predictor of Risk for the Development of Diabetes in the West of Scotland Coronary Prevention Study (2002)
    Dilys J. Freeman, John Norrie et al. Diabetes
  16. Risk factors for COVID-19-related mortality in people with type 1 and type 2 diabetes in England: a population-based cohort study (2020)
    Naomi Holman, Peter Knighton et al. The Lancet Diabetes & Endocrinology
  17. IL-33 reduces the development of atherosclerosis (2008)
    Ashley M. Miller, Damo Xu et al. The Journal of Experimental Medicine
  18. Psoriasis and Systemic Inflammatory Diseases: Potential Mechanistic Links between Skin Disease and Co-Morbid Conditions (2010)
    Batya B. Davidovici, Naveed Sattar et al. Journal of Investigative Dermatology
  19. Associations of grip strength with cardiovascular, respiratory, and cancer outcomes and all cause mortality: prospective cohort study of half a million UK Biobank participants (2018)
    Carlos Celis‐Morales, Paul Welsh et al. BMJ
  20. Maternal Obesity Is Associated with Dysregulation of Metabolic, Vascular, and Inflammatory Pathways (2002)
    Jane E. Ramsay, William R. Ferrell et al. The Journal of Clinical Endocrinology & Metabolism
  21. Effect of a behavioural intervention in obese pregnant women (the UPBEAT study): a multicentre, randomised controlled trial (2015)
    Lucilla Poston, Ruth Bell et al. The Lancet Diabetes & Endocrinology
  22. Obesity Is a Risk Factor for Severe COVID-19 Infection (2020)
    Naveed Sattar, Iain B. McInnes et al. Circulation
  23. Cardiovascular and Renal Outcomes with Efpeglenatide in Type 2 Diabetes (2021)
    Hertzel C. Gerstein, Naveed Sattar et al. New England Journal of Medicine
  24. Excess mortality and cardiovascular disease in young adults with type 1 diabetes in relation to age at onset: a nationwide, register-based cohort study (2018)
    Araz Rawshani, Naveed Sattar et al. The Lancet
  25. The changing face of diabetes complications (2016)
    Edward W. Gregg, Naveed Sattar et al. The Lancet Diabetes & Endocrinology
  26. Estimated Life Expectancy in a Scottish Cohort With Type 1 Diabetes, 2008-2010 (2015)
    Shona Livingstone, Daniel L. Levin et al. JAMA
  27. Association between active commuting and incident cardiovascular disease, cancer, and mortality: prospective cohort study (2017)
    Carlos Celis‐Morales, Donald M. Lyall et al. BMJ
  28. Age at Diagnosis of Type 2 Diabetes Mellitus and Associations With Cardiovascular and Mortality Risks (2019)
    Naveed Sattar, Araz Rawshani et al. Circulation
  29. Vitamin D concentrations and COVID-19 infection in UK Biobank (2020)
    Claire E. Hastie, Daniel Mackay et al. Diabetes & Metabolic Syndrome Clinical Research & Reviews
  30. Polygenic Risk Score Identifies Subgroup With Higher Burden of Atherosclerosis and Greater Relative Benefit From Statin Therapy in the Primary Prevention Setting (2017)
    Pradeep Natarajan, Robin Young et al. Circulation
  31. Incidence, prevalence, and co-occurrence of autoimmune disorders over time and by age, sex, and socioeconomic status: a population-based cohort study of 22 million individuals in the UK (2023)
    Nathalie Conrad, Shivani Misra et al. The Lancet
  32. Remission of Human Type 2 Diabetes Requires Decrease in Liver and Pancreas Fat Content but Is Dependent upon Capacity for β Cell Recovery (2018)
    Roy Taylor, Ahmad Al-Mrabeh et al. Cell Metabolism
  33. GLP-1 Receptor Agonists for the Reduction of Atherosclerotic Cardiovascular Risk in Patients With Type 2 Diabetes (2022)
    Nikolaus Marx, Mansoor Husain et al. Circulation
  34. Tirzepatide cardiovascular event risk assessment: a pre-specified meta-analysis (2022)
    Naveed Sattar, Darren K. McGuire et al. Nature Medicine
  35. Cardiac Troponin T and Troponin I in the General Population (2019)
    Paul Welsh, David Preiss et al. Circulation
  36. Cardiovascular risk in diabetes mellitus: epidemiology, assessment and prevention (2023)
    Nathan D. Wong, Naveed Sattar Nature Reviews Cardiology
  37. Effects of tirzepatide versus insulin glargine on kidney outcomes in type 2 diabetes in the SURPASS-4 trial: post-hoc analysis of an open-label, randomised, phase 3 trial (2022)
    Hiddo J.L. Heerspink, Naveed Sattar et al. The Lancet Diabetes & Endocrinology
  38. Obesity and cardiovascular disease: mechanistic insights and management strategies. A joint position paper by the World Heart Federation and World Obesity Federation (2022)
    Francisco López-Jiménez, Wael Almahmeed et al. European Journal of Preventive Cardiology
  39. Anthropometric measures and adverse outcomes in heart failure with reduced ejection fraction: revisiting the obesity paradox (2023)
    Jawad H. Butt, Mark C. Petrie et al. European Heart Journal
  40. Comparison of tirzepatide and dulaglutide on major adverse cardiovascular events in participants with type 2 diabetes and atherosclerotic cardiovascular disease: SURPASS‐CVOT design and baseline characteristics (2023)
    Stephen J. Nicholls, Deepak L. Bhatt et al. American Heart Journal
  41. 5-year follow-up of the randomised Diabetes Remission Clinical Trial (DiRECT) of continued support for weight loss maintenance in the UK: an extension study (2024)
    Michael EJ Lean, W. S. Leslie et al. The Lancet Diabetes & Endocrinology
  42. Effects of GLP-1 receptor agonists on kidney and cardiovascular disease outcomes: a meta-analysis of randomised controlled trials (2024)
    Sunil V. Badve, Matthew M.Y. Lee et al. The Lancet Diabetes & Endocrinology
  43. Efficacy of GLP-1 Receptor Agonists on Weight Loss, BMI, and Waist Circumference for Patients With Obesity or Overweight: A Systematic Review, Meta-analysis, and Meta-regression of 47 Randomized Controlled Trials (2025)
    Yao Hao Teo, Yao Neng Teo et al. Diabetes Care
  44. Tirzepatide and muscle composition changes in people with type 2 diabetes (SURPASS-3 MRI): a post-hoc analysis of a randomised, open-label, parallel-group, phase 3 trial (2025)
    Naveed Sattar, Ian J. Neeland et al. The Lancet Diabetes & Endocrinology

Immediate Impact

8 from Science/Nature 141 standout
Sub-graph 1 of 18

Citing Papers

Tirzepatide as Compared with Semaglutide for the Treatment of Obesity
2025 Standout
Oral Semaglutide and Cardiovascular Outcomes in High-Risk Type 2 Diabetes
2025 Standout
20 intermediate papers

Works of Naveed Sattar being referenced

Effects of GLP-1 receptor agonists on kidney and cardiovascular disease outcomes: a meta-analysis of randomised controlled trials
2024 Standout
Risk Factors, Mortality, and Cardiovascular Outcomes in Patients with Type 2 Diabetes
2018 Standout
and 20 more

Author Peers

Author Last Decade Papers Cites
Naveed Sattar 22026 14746 13539 1.2k 70.7k
Charles H. Hennekens 17141 18066 12023 577 83.9k
Albert Hofman 8820 26681 13015 1.5k 118.0k
Lewis H. Kuller 15696 19039 10323 999 76.0k
Meir J. Stampfer 25446 16948 15112 844 138.2k
Jaakko Tuomilehto 22298 12064 8795 757 59.1k
Paul Zimmet 45594 15320 21728 705 107.7k
Josef Coresh 16406 29995 13979 936 112.1k
Coen D.A. Stehouwer 15268 17268 9687 1.0k 55.7k
Eric B. Rimm 13983 10508 11321 887 100.2k
Jonathan E. Shaw 32566 9336 13463 562 78.6k

All Works

Loading papers...

Rankless by CCL
2026